Navigation Links
Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
Date:4/29/2009

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- The recent announcement of the REDUCE trial results at the American Urological Association annual meeting in Chicago brings optimism to the prostate cancer community as dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, has shown to lower by 23 percent the risk of prostate cancer in men with an increased risk of the disease.

Men's Health Network looks forward to this becoming an additional tool in the fight against prostate cancer.

The REDUCE trial is a placebo-controlled study that evaluates whether dutasteride decreases the risk of biopsy-detectable prostate cancer.

As this disease continues to strike one in six American men, with African American men having an incidence rate up to 60% higher than white men, it is important that patients and physicians engage in a meaningful conversation about prostate cancer, an individual's risk of getting the disease, and the value of early detection and prevention.

Scott Williams, Vice President, Men's Health Network commented, "We continually stress the importance for men to receive a baseline Prostate Specific Antigen or PSA and physical exam of the prostate at age 40 and to engage in a continual dialogue with their physician about their individual risk and need for annual prostate exams. It could mean the difference between living with the disease or dying from the disease."

PSA is currently the most effective tool physicians and patients have to detect a disease that kills an estimated 28,000 men a year in the US.

In addition to the approximately 200,000 men who are diagnosed with prostate cancer each year, we must remember that the disease can have a devastating effect on entire families and communities. Spouses, significant others, and children are often emotionally, financially, and physically strained and the diagnosis reaches beyond the family to impact friendships, employers, and churches.

"It is also important to note that families can impact the prevention and early detection of prostate cancer," said Theresa Morrow of Women Against Prostate Cancer. "Just a little encouragement from a spouse or family member can get a man to the doctor for prostate screening."

The REDUCE trial is the first step in a paradigm shift in the way prostate cancer is viewed, changing the conversation to focus on the value of prevention and early detection of this deadly disease.


'/>"/>
SOURCE Men's Health Network
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Another Study Links Fluoride to Bone Cancer
2. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
3. Facet Solutions, Inc. Expands U.S. Pivotal Study With Next Generation Implant System
4. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
5. An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients
6. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
7. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
10. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
11. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... LAKE OSWEGO, Ore. , Dec. 5, 2016 /PRNewswire/ ... in the BioInsight clinical study. The study evaluates the ... 2 insertion procedure in an office setting. ... ProMRI ® technology that is placed underneath a ... atrial fibrillation and syncope (fainting). Atrial fibrillation is a ...
(Date:12/5/2016)... Calif. , Dec. 5, 2016 Sanovas, ... technology accelerator, announced today the launch of its wholly owned ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO ... ... There ...
(Date:12/5/2016)... Dec. 5, 2016  Wellbridge Health and Gateway Health proudly ... solutions to Medicare and Medicaid plan members with specific high ... the unique needs of this group of consumers, Wellbridge combines ... philosophies to provide insight into members, daily behaviors and lifestyle. ... , , ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... BSI and Brenntag Canada ... States and Canada for distribution of their natural fruits and beverage colorants ... is an exciting addition to our Life Sciences product portfolio,” said Steve Brauer, President ...
(Date:12/5/2016)... ... 2016 , ... Sideline Products is a Southern York County Pennsylvania-based premier designer ... and the horse. Smaller saddles can pinch and irritate the horse creating safety issues ... properly fitted western saddle so it does not impact the comfort or performance of ...
(Date:12/5/2016)... , ... December 05, 2016 , ... “Life Will Never ... a supportive family and friends. “Life Will Never Be The Same” is the creation ... course in writing children's books and holds a degree in Christian religion and philosophy ...
(Date:12/5/2016)... ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the Retina Group of ... York was founded by James M. Maisel, MD and has been providing tertiary medical and ... followed a legacy of surpassing expectations amongst her peers. Growing up in a family ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ensure moisture measurements are consistently correct. However, regular performance testing is often ... TOLEDO offers a solution: SmartCal™ . This innovative test substance offers ...
Breaking Medicine News(10 mins):